Trulicity Cost in Michigan 2026: Prices, Insurance, Medicaid, and Alternatives

What Is the Cash Price of Trulicity in Michigan in 2026?

Trulicity's manufacturer list price set by Eli Lilly is $931 per month in 2026, and Michigan retail pharmacies generally reflect that figure for cash-paying patients. Without insurance or a savings program, a four-week supply of any approved dose (0.75 mg, 1.5 mg, 3 mg, or 4.5 mg) costs approximately the same amount because Lilly prices all four pen strengths identically per carton.

That $931 figure represents the Wholesale Acquisition Cost (WAC), the benchmark most pharmacies use when no third-party coverage applies. Real transaction prices can drift slightly above or below WAC depending on pharmacy markup, but the variance across Michigan chains is narrow. GoodRx-negotiated prices in Michigan have ranged between $870 and $940 per four-pen carton in early 2026, still far above what most patients on fixed incomes can sustain long-term.

Dulaglutide belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist class. The FDA approved the 0.75 mg and 1.5 mg doses in September 2014 for type 2 diabetes management, with the 3 mg and 4.5 mg doses added in 2020. [1] The REWIND cardiovascular outcomes trial (N=9,901, median follow-up 5.4 years) published in The Lancet demonstrated that dulaglutide 1.5 mg once weekly reduced the composite of major adverse cardiovascular events by 12% vs. placebo (HR 0.88 to 95% CI 0.79, 0.99, P<0.026) in patients with type 2 diabetes who had or were at risk for cardiovascular disease. [2] That cardiovascular data strengthened the case for payers to cover the drug, but it has not materially lowered the cash price.

The American Diabetes Association 2024 Standards of Care recommend GLP-1 receptor agonists as preferred agents when cardiovascular disease, heart failure, or chronic kidney disease is present, independent of baseline HbA1c. [3] That guideline language directly influences Michigan Medicaid and commercial plan formulary decisions.

Does Michigan Medicaid Cover Trulicity?

Michigan Medicaid covers dulaglutide (Trulicity) on its preferred drug list, but coverage requires a prior authorization (PA) in most Medicaid managed care plans operating in the state.

To obtain PA, prescribers typically must document an HbA1c at or above the plan's threshold (commonly 7.5% or higher), confirm the patient carries a type 2 diabetes diagnosis, and show that metformin or another first-line agent was tried or is contraindicated. Some plans add a step-therapy requirement for a sulfonylurea before approving a GLP-1. Once PA is granted, Michigan Medicaid beneficiaries generally pay $0 to $3 per fill depending on their specific plan. The Michigan Department of Health and Human Services publishes the Medicaid covered outpatient drugs list, which specifies PA criteria by drug class. [4]

Michigan's Medicaid program serves roughly 2.9 million enrollees as of 2024, according to CMS enrollment data, and type 2 diabetes is among the most prevalent conditions in that population. [5] Patients who are denied PA have the right to file a formal appeal; many overturned denials hinge on documenting cardiovascular comorbidities consistent with the REWIND trial's enrolled population. [2]

The Endocrine Society's 2023 clinical practice guideline on type 2 diabetes pharmacotherapy states: "GLP-1 receptor agonists with proven cardiovascular benefit are recommended for patients with type 2 diabetes and established or high-risk cardiovascular disease, regardless of HbA1c." [6] Citing that language in a PA appeal letter has helped many Michigan providers secure approvals.

Which Commercial Insurance Plans Cover Trulicity in Michigan?

Most major commercial insurers operating in Michigan, including Blue Cross Blue Shield of Michigan, Priority Health, McLaren Health Plan, and Meridian, place dulaglutide on their formularies, typically at Tier 3 or Tier 4 specialty status.

Tier 3 copays in Michigan commercial plans averaged $50 to $80 per four-week supply in 2025, according to BCBS Michigan formulary filings. Tier 4 specialty placement raises that to $100 to $200 or more per fill before the Eli Lilly savings card is applied. Step-therapy protocols requiring a trial of metformin or a generic GLP-1 (none yet exist for dulaglutide in the U.S.) are common but may be bypassed when cardiovascular indications are documented. [7]

Employer-sponsored plans governed by ERISA vary widely. Some Michigan employers have moved GLP-1 agents to a dedicated obesity/diabetes specialty tier with separate deductibles. Patients should request the plan's full formulary, confirm the drug's tier status, and ask whether the Eli Lilly savings card can reduce the cost-share.

Federal marketplace plans (ACA exchange plans in Michigan) are required to cover at least one drug per class, but "dulaglutide" specifically may not be the covered agent on every plan. Checking the plan's drug list at healthcare.gov before enrollment reduces surprises. [8]

How Does the Eli Lilly Savings Card Work in Michigan?

Eli Lilly's Trulicity savings card (marketed under the Lilly Cares and Lilly Insulin Value Program umbrellas) allows eligible commercially insured Michigan patients to pay as little as $25 to $35 per month for a 30-day supply, subject to a monthly cap that Lilly adjusts periodically.

The card is not valid for Medicare Part D, Medicaid, or any other government-funded program. Patients must have commercial insurance that covers Trulicity, and the card acts as secondary payer to reduce the remaining copay. Enrollment is completed online at Lilly's patient support portal. [9] Patients without insurance at all are not eligible for this particular card but may qualify for Lilly's separate patient assistance program (Lilly Cares Foundation), which provides Trulicity at no cost to qualifying low-income patients who meet income thresholds (generally at or below 400% of the federal poverty level). [10]

For a Michigan household of two, 400% FPL in 2026 equates to roughly $79,840 annual income. Patients above that threshold but below their plan's out-of-pocket maximum may still benefit substantially from the copay card on a month-to-month basis.

Is Compounded Dulaglutide Legal in Michigan?

Licensed 503A compounding pharmacies in Michigan may legally prepare dulaglutide preparations for individual patients when a valid prescription is presented, provided the compounded product meets state Board of Pharmacy standards and federal USP <797> guidelines for sterile compounding.

The key legal distinction is between 503A pharmacies (patient-specific, state-licensed, cannot sell to wholesale) and 503B outsourcing facilities (bulk compounding for healthcare providers, FDA-registered). Michigan has active 503A pharmacies capable of sterile injectable compounding. These pharmacies source the active pharmaceutical ingredient from registered suppliers, and the finished product is not FDA-approved, meaning potency and sterility verification rests entirely on the compounding pharmacy's quality-assurance process.

The FDA has not placed dulaglutide on its Shortage List as of mid-2025 (unlike semaglutide, which appeared on that list in 2022 and drove a surge of compounding activity). [11] This matters because 503B outsourcing facilities can only compound a drug that appears on the shortage list or that is a copy of an FDA-approved drug with documented clinical need. Without shortage-list status, 503B facilities face tighter restrictions, making 503A the primary legal route for compounded dulaglutide in Michigan.

Cost varies by pharmacy and dose, but compounded dulaglutide preparations have been priced in the $150 to $350 per month range at Michigan 503A pharmacies, substantially below the $931 WAC for branded Trulicity. Patients should verify that their compounding pharmacy holds a current Michigan Board of Pharmacy license and request a Certificate of Analysis for each batch. [12]

The Michigan Board of Pharmacy (part of LARA, the Department of Licensing and Regulatory Affairs) publishes its licensed pharmacy database online, making verification straightforward. [13]

Can a Michigan Patient Get Trulicity Through Telehealth?

Michigan law permits telehealth prescribing of dulaglutide for type 2 diabetes when a qualifying clinical relationship exists and when the prescriber holds an active Michigan medical license.

The Michigan Public Health Code and the 2020 telehealth expansion (Public Act 45 of 2020) allow physicians, NPs, and PAs to establish a patient-provider relationship via synchronous video visit, after which a GLP-1 prescription may be issued electronically. [14] This means a Michigan patient can receive a Trulicity prescription without an in-person office visit, provided the telehealth provider reviews labs, confirms the type 2 diabetes diagnosis, and documents cardiovascular risk factors or HbA1c history.

HealthRX providers follow a structured intake that mirrors ADA 2024 Standards of Care criteria before initiating any GLP-1 agent. [3] That includes reviewing baseline HbA1c, eGFR, a personal and family history of medullary thyroid carcinoma or MEN 2 syndrome (both contraindications to GLP-1 agonists per the FDA label [1]), and current medication list for interaction review.

Telehealth-prescribed Trulicity is dispensed at any Michigan retail pharmacy or through mail-order pharmacy. The prescription itself is covered under the same insurance rules as an in-person prescription. Patients on Michigan Medicaid still require PA regardless of prescribing channel.

What Are the Cheapest Ways to Get Trulicity in Michigan?

Ranked from lowest to highest expected monthly out-of-pocket cost, Michigan patients in 2026 have these realistic options.

Lilly Cares Foundation patient assistance provides Trulicity at no charge to qualifying uninsured or underinsured patients. Income documentation is required and approval can take two to four weeks. [10] Michigan Medicaid with PA reduces cost-share to $0 to $3 per fill for eligible beneficiaries. [4] The Eli Lilly savings card cuts commercial copays to roughly $25 to $35 per month for insured patients who are not on government programs. [9] Compounded dulaglutide from a licensed Michigan 503A pharmacy runs approximately $150 to $350 per month cash pay. [12] GoodRx coupons at Michigan retail pharmacies pull the branded price to roughly $870 to $940, still close to list price. Full cash pay without any assistance is $931 per fill.

Patients who need GLP-1 therapy but cannot access any of the above programs should ask their provider about alternative GLP-1 agents. Exenatide extended-release (Bydureon BCise) and liraglutide (Victoza) have older patents and different formulary placements that may cost less on certain Michigan plans, though neither has dulaglutide's cardiovascular outcome data from REWIND. [2]

Clinical Efficacy Data That Supports Coverage Decisions

Payers and prescribers in Michigan cite specific trial results when making formulary and PA decisions, and understanding those numbers helps patients advocate for themselves.

The REWIND trial enrolled 9,901 adults with type 2 diabetes (mean age 66.2 years, mean HbA1c 7.3%, 69% with prior cardiovascular disease) and followed them for a median of 5.4 years. Dulaglutide 1.5 mg once weekly reduced the three-point MACE composite (nonfatal MI, nonfatal stroke, or cardiovascular death) by 12% compared to placebo (HR 0.88 to 95% CI 0.79, 0.99). [2] The number needed to treat over five years was approximately 71.

The AWARD-5 trial (N=1,098) compared dulaglutide 1.5 mg to sitagliptin 100 mg in metformin-treated patients. Dulaglutide produced a mean HbA1c reduction of 1.1% vs. 0.4% for sitagliptin at 52 weeks (P<0.001). [15] This trial is frequently cited in PA appeals when a plan requires documented superiority over DPP-4 inhibitors.

Body-weight reduction with dulaglutide 1.5 mg averaged 2.9 kg at 26 weeks in AWARD-5, a modest effect compared to higher-dose semaglutide but clinically meaningful for glycemic management. [15] Michigan plans that have carved out GLP-1 agents strictly for weight loss rather than diabetes may deny coverage for patients whose primary indication is obesity without a concurrent type 2 diabetes diagnosis, an important distinction from semaglutide 2.4 mg (Wegovy), which carries an FDA obesity indication. [16]

The ADA 2024 Standards of Care set a target HbA1c of below 7.0% for most non-pregnant adults with type 2 diabetes, with individualization based on hypoglycemia risk, life expectancy, and patient preference. [3] Meeting that target with dulaglutide is achievable in the majority of patients who tolerate the drug, supporting both clinical and economic arguments for coverage.

Side Effects and Contraindications Michigan Prescribers Monitor

Dulaglutide carries an FDA black box warning for the risk of thyroid C-cell tumors observed in rodent studies. The drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with MEN 2 syndrome. [1] Michigan prescribers ordering the drug through telehealth or in-office must document that contraindication screening occurred.

The most common adverse effects are gastrointestinal: nausea (12.4% at 1.5 mg in pooled AWARD trials), diarrhea (8.9%), vomiting (5.8%), and abdominal pain. [1] These effects are dose-dependent and typically peak during the first four to eight weeks of treatment, then attenuate. Starting at 0.75 mg for four weeks before escalating to 1.5 mg is the FDA-recommended approach for tolerability. [1]

Acute pancreatitis has been reported with GLP-1 agonists as a class. Prescribers should advise patients to stop dulaglutide and seek evaluation for severe, persistent abdominal pain. The FDA's MedWatch database captures ongoing post-market safety reports for dulaglutide. [17]

Kidney function generally does not require dose adjustment, a practical advantage in Michigan's Medicaid population where diabetic nephropathy is prevalent. The REWIND trial showed a reduction in new macroalbuminuria with dulaglutide (HR 0.77 to 95% CI 0.68, 0.87), supporting renal protection as a secondary benefit. [2]

How Michigan Providers Document Medical Necessity for PA

Prior authorization for dulaglutide under Michigan Medicaid and most commercial plans follows a predictable set of documentation requirements. Providers who front-load their clinical notes with these elements see faster approvals.

Required elements typically include: documented type 2 diabetes diagnosis with a recent HbA1c result; evidence that metformin was tried and either failed or is contraindicated (e.g., eGFR <30 mL/min/1.73m2 or lactic acidosis history); relevant cardiovascular comorbidities (ASCVD, heart failure, CKD stage 3 or above); and the specific dose requested. Some plans require the note to state the patient cannot achieve glycemic control on current regimen. The ADA/EASD 2022 consensus statement on management of hyperglycemia in type 2 diabetes recommends GLP-1 agonists as the preferred injectable option when weight loss is a priority or when cardiovascular protection is needed, language that maps directly onto most PA criteria. [18]

The Michigan Medicaid managed care plans, including Molina, UnitedHealthcare Community Plan Michigan, and Blue Cross Complete, publish their PA criteria publicly. Checking the plan's specific criteria before submitting the request saves time and avoids unnecessary denials. [4]